Importantly, Car-B7H3-γδT cells can recognize tumors via B7H3-Car and also possess the ability to eliminate tumors through phosphoantigen recognition. Our study showed that Car-B7H3-γδT cells were more potent than unmodified Vγ9Vδ2 T cells at inhibiting GBM cell proliferation in vitro and improving the overall survival of tumor-bearing mice, suggesting that genetic modification of Vγ9Vδ2 T cells may enhance the therapeutic efficacy and clinical outcomes of Vγ9Vδ2 T cell-based immunotherapy for GBM. The gene discussed is CD276; the disease is neoplasm.